[Effect of gentamycin in combination with prodigiozan on the immunological reactivity of the body].
The effect of gentamicin sulphate and its combination will prodigiozan on antibody formation in experiments and the levels of the immunobiologic reactivity of patients with purulent inflammatory processes was studied with a purpose of developing rational schemes of antibiotic therapy of infectious diseases. A decrease in the titers of the antibodies to Aeromonas and the number of antibody-forming cells in the spleen was noted on repeated administration of gentamicin to albino mice in a dose of 20 mg/kg. This was prevented by the use of prodigiozan in a dose of 500 micrograms/kg once every 4 days. The use of gentamicin in patients with purulent inflammatory diseases in doses of 40 or 80 mg twice a day for 7--10 days had no significant effect on the titers of IgA, IgG, IgM, lysozyme blood serum levels, serum bactericidal activity and absorption activity of the peripheral blood neutrophils. Still, it induced a marked suppression of the neutrophil digestive capacity as compared to the initial levels, especially on administration of gentamicin in a dose of 40 mg twice a day. An increase in the level of IgM and no suppression of the neutrophil digestive capacity were noted after completion of the therapy in the patients treated with gentamicin administered in a dose of 40 mg twice a day and prodigiozan administered in a dose of 50 micrograms once every 4 days. It is recommended to use prodigiozan in combinaed therapy with gentamicin for correction of the changes in the specific and nonspecific protective forces of the host.
D000333:Aeromonas / Q000276:immunology; D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis; D000917:Antibody Formation / Q000187:drug effects*; D000921:Antibody-Producing Cells / Q000187:drug effects; D001770:Blood Bactericidal Activity / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D005839:Gentamicins / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects*; D007114:Immunization; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D008297:Male; D051379:Mice; D009113:Muramidase / Q000097:blood; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D011354:Prodigiozan / Q000276:immunology*; D013530:Surgical Wound Infection / Q000188:drug therapy
D000907:Antibodies, Bacterial; D005839:Gentamicins; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D011135:Polysaccharides, Bacterial; D011354:Prodigiozan; D009113:Muramidase
Vliianie gentamitsina v sochetanii s prodigiozanom na immunologicheskuiu reaktivnost' organizma.